57th American College of Cardiology Annual Scientific Session


The American College of Cardiology (ACC) is holding its Annual Scientific Session and Innovation in Intervention. The annual meeting of the ACC is unsurpassed among clinical cardiology meetings and is one of the most highly attended and respected events in cardiovascular medicine. It is a forum for the latest and most innovative findings in cardiovascular science, as well as the most clinically relevant practical applications. For more information call (202) 375-6000 or visit www.cardiosource.org/acc.

The peak-interest clinical trials at the American College of Cardiology (ACC) Scientific Sessions, which took place from March 29 to April 2, 2008, are generally ushered into the high-profile Late-Breaking Clinical Trials sessions. This year, the ENHANCE trial (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) was precluded from the “Late-Breakers” because a peek at the unexpectedly disappointing data had already been afforded in January.Amid pre-meeting publicity about allegedly inappropriate data delays (and a Congressional hearing delving into them), the ACC created a special plenary session “Showcase” presentation of the data with a review panel for comment. The ENHANCE findings intensified interest in both non-lipid-lowering benefits of statins and non-statins for lipid lowering. This 57th ACC conference hosted a record 29,000 attendees in Chicago, Illinois.